Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

[1]  L. Cui,et al.  Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype , 2008, Antimicrobial Agents and Chemotherapy.

[2]  L. Cui,et al.  Improved Antimicrobial Activity of Linezolid against Vancomycin-Intermediate Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[3]  M. Wootton,et al.  Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA , 2008, Journal of Clinical Microbiology.

[4]  A. Rubio,et al.  Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis , 2007, Antimicrobial Agents and Chemotherapy.

[5]  F. Tenover,et al.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Wootton.  The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero--VISA detection methods. , 2006, International journal of antimicrobial agents.

[7]  A. MacGowan,et al.  A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides , 2006, Journal of Clinical Microbiology.

[8]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[9]  L. Friedman,et al.  Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[10]  J. Patel,et al.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Eliopoulos,et al.  Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin , 2006, Antimicrobial Agents and Chemotherapy.

[12]  L. Cui,et al.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[13]  B. Wilkinson,et al.  The escalating challenge of vancomycin resistance in Staphylococcus aureus. , 2004, Current drug targets. Infectious disorders.

[14]  P. Ward,et al.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. McAllister,et al.  Pulsed-Field Gel Electrophoresis Typing of Oxacillin-Resistant Staphylococcus aureus Isolates from the United States: Establishing a National Database , 2003, Journal of Clinical Microbiology.

[16]  M. Kitzis,et al.  Vancomycin-resistant Staphylococcus aureus: no apocalypse now. , 2003, Clinical Microbiology and Infection.

[17]  A. MacGowan,et al.  Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides , 2001, Journal of Clinical Microbiology.

[18]  A. MacGowan,et al.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.

[19]  Michael J. Rybak,et al.  In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains , 2000, Antimicrobial Agents and Chemotherapy.

[20]  R. Jayaswal,et al.  Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds , 2000, Antimicrobial Agents and Chemotherapy.

[21]  K. Hiramatsu,et al.  Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. , 1998, The Journal of antimicrobial chemotherapy.

[22]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[23]  A. Patchefsky,et al.  Case report 3 , 1976, Skeletal Radiology.

[24]  Clinical,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .

[25]  J. Mcgowan,et al.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. , 2003, Microbial drug resistance.

[26]  A. MacGowan,et al.  Heterogeneous resistance to vancomycin in Staphylococcus aureus. , 2000, The Journal of antimicrobial chemotherapy.

[27]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[28]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .